Sanofi introduces new packaging for Priftin

Sanofi introduces new packaging for Priftin®
Sanofi introduces new packaging for Priftin® | Courtesy of
Sanofi recently introduced its new packing for Priftin (rifapentine) specially for treating latent tuberculosis infections (LTBI) in people who are 2 or older and have a high risk of developing tuberculosis (TB).

The new packaging divides the drug into 24 packs and 32 packs. The purpose is to better manage the regimens of the doses for latent as well as active TB. For the 24 packaging, each individual tablet has prints on the foil backing and perforated tablet blisters. These packages have a shelf life of approximately three years.

"For more than 50 years, Sanofi has provided treatment and programs that equip patients and their health care providers to fight TB," Paul Chew, Sanofi's global chief medical officer, said. "We are proud to introduce packaging and extended shelf-life that reinforces our sustained commitment to the TB community." 

LTBI cannot be transmitted to other people, and patients with LTBI don’t experience any symptoms. The World Health Organization reports approximately 13 million Americans have LTBI. Between 5 and 10 percent of these patients will have TB if they do not receive treatments.

Priftin, an antimycobacterial, first received approval for use in the US in 1998. It is often combined with an additional antituberculosis drug in order to treat active pulmonary TB, which is the result of Mycobacterium TB.

Organizations in this Story

Sanofi US

Want to get notified whenever we write about Sanofi US ?
Next time we write about Sanofi US, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.